Ashlie Santaliz Casiano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashlie Santaliz Casiano has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Zeynep Madak-Erdogan
Division of Nutritional Sciences, University of Illinois, Urbana-Champaign, Urbana, IL, USA.
36 shared publications - Akshara Singareeka Raghavendra
Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center , Houston, TX
35 shared publications Ayca Nazli Mogol
35 shared publicationsBen Ho Park
35 shared publications- Benita S. Katzenellenbogen
Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, USA
35 shared publications - Christine Chien
Carle Illinois College of Medicine, Champaign, IL
35 shared publications
Latest Publications
- 21 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF13
Single-Cell Profiling of Peripheral Blood Mononuclear Cells in Diverse Men with Prostate Cancer Reveals a Fatal Disease–Associated Immune Signature
Alterations in peripheral immunity may contribute to fatal prostate cancer and the excessive disease burden among African American (AA) men. Thus, we investigated peripheral immunity in patients with prostate cancer in association with disease outcome and AA descent. We performed single-cell RNA and T-cell receptor (TCR) sequencing using peripheral blood mononuclear cells (PBMC) from a cohort of 43 patients with prostate cancer with survival follow-up and 16 healthy controls. Analyzing 273,229 high-quality PBMCs, we observed that men who developed fatal prostate cancer (n = 20) distinctively expressed the LAG3 and TIGIT exhaustion markers in their CD8+ T effector memory cells (CD8 TEM). These men also showed a loss of type 2 conventional dendritic cells (cDC2). Further analyses revealed additional transcriptome-inferred functional differences in cDC2, CD16+ monocytes, and CD8 TEM when comparing men with and without fatal disease. Those describe cDC2 as immunosuppressed, CD16+ monocytes as proinflammatory but less cytotoxic, and CD8 TEM as chronically activated in patients with fatal disease. Comparing AA with European American patients, we observed upregulated LAG3 and TIGIT in AA PBMC. For cDC2 and CD16+ monocytes, fatal disease and AA patients showed shared marker expression. Furthermore, TCR profiling discovered an overrepresentation of large, hyperexpanded clonotypes and a lower TCR diversity among fatal disease and AA patients. Lastly, the CD8 TEM functional status and LAG3 expression in PBMC emerged as candidate predictors of disease fatality. We conclude that peripheral immunity may distinctly vary in association with disease outcome and AA descent of patients with prostate cancer.
- 21 September 2026
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- p. OF1-OF13
Single-Cell Profiling of Peripheral Blood Mononuclear Cells in Diverse Men with Prostate Cancer Reveals a Fatal Disease–Associated Immune Signature
Alterations in peripheral immunity may contribute to fatal prostate cancer and the excessive disease burden among African American (AA) men. Thus, we investigated peripheral immunity in patients with prostate cancer in association with disease outcome and AA descent. We performed single-cell RNA and T-cell receptor (TCR) sequencing using peripheral blood mononuclear cells (PBMC) from a cohort of 43 patients with prostate cancer with survival follow-up and 16 healthy controls. Analyzing 273,229 high-quality PBMCs, we observed that men who developed fatal prostate cancer (n = 20) distinctively expressed the LAG3 and TIGIT exhaustion markers in their CD8+ T effector memory cells (CD8 TEM). These men also showed a loss of type 2 conventional dendritic cells (cDC2). Further analyses revealed additional transcriptome-inferred functional differences in cDC2, CD16+ monocytes, and CD8 TEM when comparing men with and without fatal disease. Those describe cDC2 as immunosuppressed, CD16+ monocytes as proinflammatory but less cytotoxic, and CD8 TEM as chronically activated in patients with fatal disease. Comparing AA with European American patients, we observed upregulated LAG3 and TIGIT in AA PBMC. For cDC2 and CD16+ monocytes, fatal disease and AA patients showed shared marker expression. Furthermore, TCR profiling discovered an overrepresentation of large, hyperexpanded clonotypes and a lower TCR diversity among fatal disease and AA patients. Lastly, the CD8 TEM functional status and LAG3 expression in PBMC emerged as candidate predictors of disease fatality. We conclude that peripheral immunity may distinctly vary in association with disease outcome and AA descent of patients with prostate cancer.
- Open Access
- 2 September 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 5083-5098
Multiomic Analysis Links Neighborhood Disadvantage to Inflammatory Proteins and Tumorigenic Markers in ER+ Breast Cancer Plasma and Tumor Samples
Residing in disadvantaged neighborhoods has been linked to worsened survival among Black women with estrogen receptor-positive (ER+) breast cancer (BC), yet the underlying multiomic alterations remain underexplored. To investigate associations between neighborhood deprivation and pretreatment steroid hormones, untargeted metabolites, inflammatory proteins, and tumoral gene expression in women with primary ER+ BC and cancer-free controls, pretreatment plasma was collected from ER+ BC patients (n = 91) and controls (n = 141) across three Chicago hospitals. Area deprivation index (ADI) was calculated per participant. Plasma was analyzed via targeted steroid hormone and untargeted metabolomics assays, and Olink's inflammatory protein panel. Tumor samples (n = 71) were analyzed using the Nanostring Breast Cancer 360 panel. Single-omic analysis and multiomics integration were performed. Elevated inflammatory proteins were observed in cases and controls from disadvantaged neighborhoods (p < 0.05), and tumoral gene expression showed upregulation of inflammatory and proliferation-related genes (p < 0.05). Patients from deprived areas exhibited higher inflammation and antioxidant depletion even within the same tumor grade (p < 0.05). Neighborhood deprivation correlates with pro-inflammatory, proliferative multiomic profiles that may underlie worsened outcomes.
- 2 September 2025
- Published by American Chemical Society (ACS) in Journal of Proteome Research
- Vol. 24 (10) , 5083-5098
Open AccessMultiomic Analysis Links Neighborhood Disadvantage to Inflammatory Proteins and Tumorigenic Markers in ER+ Breast Cancer Plasma and Tumor Samples
Residing in disadvantaged neighborhoods has been linked to worsened survival among Black women with estrogen receptor-positive (ER+) breast cancer (BC), yet the underlying multiomic alterations remain underexplored. To investigate associations between neighborhood deprivation and pretreatment steroid hormones, untargeted metabolites, inflammatory proteins, and tumoral gene expression in women with primary ER+ BC and cancer-free controls, pretreatment plasma was collected from ER+ BC patients (n = 91) and controls (n = 141) across three Chicago hospitals. Area deprivation index (ADI) was calculated per participant. Plasma was analyzed via targeted steroid hormone and untargeted metabolomics assays, and Olink's inflammatory protein panel. Tumor samples (n = 71) were analyzed using the Nanostring Breast Cancer 360 panel. Single-omic analysis and multiomics integration were performed. Elevated inflammatory proteins were observed in cases and controls from disadvantaged neighborhoods (p < 0.05), and tumoral gene expression showed upregulation of inflammatory and proliferation-related genes (p < 0.05). Patients from deprived areas exhibited higher inflammation and antioxidant depletion even within the same tumor grade (p < 0.05). Neighborhood deprivation correlates with pro-inflammatory, proliferative multiomic profiles that may underlie worsened outcomes.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Table from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy
Supplementary Figure from Targeting Metabolic Adaptations in the Breast Cancer–Liver Metastatic Niche Using Dietary Approaches to Improve Endocrine Therapy Efficacy